Market revenue in 2024 | USD 89.7 million |
Market revenue in 2030 | USD 66.2 million |
Growth rate | -5.3% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.97% in 2024. Horizon Databook has segmented the Brazil anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil’s anti-VEGF therapeutics market is anticipated to witness lucrative growth over the forecast period, owing to factors such as increasing government initiatives and a growing patient pool. An article suggests that the prevalence of AMD was around 15.1% in the population aged above 60 years. In addition, around 30.5% of AMD patients belong to the 80 years or above age group.
Moreover, increase in demand for biosimilar drugs can help increase the customer pool for biosimilar players in the market. The annual costs of treating one patient in Brazil were USD 476.65 and USD 11,469.39 for bevacizumab & ranibizumab, respectively.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account